A Study of PHN-012 in Patients With Advanced Solid Tumors
Phase 1
165
about 2.7 years
18+
11 sites in CA, DC, MA +6
What this study is about
This trial is testing a new treatment called PHN-012 for people with advanced solid tumors. The goal is to see if the treatment is safe and effective, as well as how it affects the body's immune system and how it moves through the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take PHN-012
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Overall response rate (ORR) (Phase 1b), Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1a)
Secondary: Best overall response (BOR) (Phase 1a and 1b), Disease control rate (DCR) (Phase 1a and 1b), Overall survival (OS) (Phase 1a and 1b), Pharmacokinetics, AUC of total antibody (Phase 1a and 1b), Pharmacokinetics, AUC of total free payload (Phase 1a and 1b), Pharmacokinetics, Cmax of free payload (Phase 1a and 1b), Pharmacokinetics, Cmax of total antibody (Phase 1a and 1b), Pharmacokinetics, Tmax of free payload (Phase 1a and 1b)
Oncology